Cure8 news brief
Placebo response rates and their predictors can meaningfully influence IBD trial outcomes and how we interpret drug efficacy. Understanding which patient or trial features raise or lower placebo rates can help design more reliable Crohn’s disease studies.
Clinical trialists, gastroenterology researchers, clinicians who read IBD trials, and patient advocates interested in trial design
The study combined individual patient data from multiple phase 2/3 placebo-controlled Crohn’s trials (2010–2021) and found induction placebo clinical response ~27% and maintenance ~32%, with lower placebo rates when baseline CRP was higher and higher rates with greater albumin and BMI. Prior anti‑TNF failure was associated with reduced placebo response.
The authors suggest using eligibility criteria, stratification by biomarkers and patient features, and careful trial design (eg, single-country vs multinational) to reduce variability from placebo effects.
Findings come from pooled individual-patient data from multiple phase 2/3 trials (2010–2021). The report focuses on trial design and associations (not on treatment efficacy); details are based on the article’s summary of the meta-analysis.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Understanding and quantifying placebo-driven endoscopic changes can improve design and interpretation of Crohn’s disease trials, which may ultimately speed development of effective therapies and clarify who benefits from...
This study provides real-world 12-month results for people with moderate-to-severe Crohn’s disease or ulcerative colitis treated with biologic or small-molecule therapies in Bahrain—showing many patients improved...
